Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
about
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectivesCardiovascular Effects of Glucagon-Like Peptide-1 Receptor AgonistsSGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?Clinically and pharmacologically relevant interactions of antidiabetic drugsCardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic MedicationsBeat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agentsGlucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndromePractical combination therapy based on pathophysiology of type 2 diabetesCardiovascular effects of incretin therapy in diabetes care.Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.The pathophysiology of hypertension in patients with obesity.Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes.Gastrointestinal intervention ameliorates high blood pressure through antagonizing overdrive of the sympathetic nerve in hypertensive patients and rats.Effects of glucagon-like peptide-1 agents on left ventricular function: systematic review and meta-analysis.Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome.Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial.Effectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients.GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Effects of glucagon-like peptide-1 receptor agonists on renal functionGlucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.Selective beneficial cardiometabolic effects of vertical sleeve gastrectomy are predominantly mediated through glucagon-like peptide (GLP-1) in Zucker diabetic fatty rats.Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies.Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.Is there a role for the incretin system in blood pressure regulation?Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.GLP-1 Agonists and Blood Pressure: A Review of the Evidence.Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Cardiovascular safety of therapies for type 2 diabetes.The impact of insulin resistance on the kidney and vasculature.Gastrointestinal-Renal Axis: Role in the Regulation of Blood PressureGLP-1 receptor agonists in the treatment of polycystic ovary syndrome.Gastrointestinal Tract: a Promising Target for the Management of Hypertension.A review of chemical therapies for treating diabetic hypertension.Case Study: Use of GLP-1 Receptor Agonist in a Patient on Intensive Insulin Therapy.
P2860
Q26746901-B1246650-89AF-4B12-8362-B2C0ECEFCF42Q26749495-F584B1AF-1F3A-4663-807A-CEF0C6447879Q26750510-44D602EF-0C62-4321-9F18-27D256196FC7Q26752468-E3369B54-EAB4-42D6-A165-A5EB60E00B4AQ26824616-94DE524B-A74A-4627-98A1-65278F47A086Q27010669-32218EDE-1FB4-4718-8118-3684E43F60DBQ28070416-48E9F86D-C833-47FA-89AA-0B1A4AA1BC44Q28076530-BF9830DF-A245-4714-B713-36F4309C047EQ34171759-3F772EBF-FAD6-42F9-B09D-9825BD507A74Q34509910-857C2573-B7FE-4A2D-9682-8741DE267EFCQ35021492-4F681775-FA87-487A-8F54-4053B5A36256Q35044151-DF0F54D7-EE6C-4063-B370-B2ADE9424641Q35070635-FD2D9448-5757-4913-BE86-5818DAB430B1Q35227453-B622D22D-3DFF-4BFA-A63E-B30D8FB9E4B4Q35411439-DB70366F-1F00-4FBD-BCD9-DC3FB4C2C5BFQ35641060-BAC11A41-0E3E-421E-BBEA-CD677ED5862CQ35709661-903B0532-A75A-4ACA-9729-9A9C1F1E030DQ36082402-25521C5F-D22D-4869-8CCC-76AFF60A9343Q36406821-9A65C0E8-2C5A-4E53-92FF-2372712341ADQ37232679-43ABE1E6-4069-405F-A020-03A4978A84DFQ37402786-9508A6A0-4B96-4FEF-AF35-772E0EA337C3Q37439663-E2126E01-4C76-4FBE-8D2E-3A7A68833E3CQ37562586-9CA1E4E2-E493-4A62-9353-6FF4A65B10EDQ37611715-B538D780-862E-4DE5-95B2-B1DC25EA983FQ38154623-55E16B71-C31F-4B63-AAC3-16FD938F8D75Q38179267-BFFD3D56-6F86-4FB5-BB32-A200C878D5B3Q38182499-0F771508-0B02-4697-A58B-3050CF09D131Q38199984-4B75E085-9344-45A8-B3AB-3669F40BA2C5Q38235219-9EEBBEA8-BDF6-469A-8CEC-DCE4E6707DB6Q38587097-6A64DB9A-EBFA-4B8A-88CF-B8A9AA6BC6D6Q38709406-95E20F7D-170D-4B6F-811E-9555E65E341CQ38753804-3B11F400-99A5-474B-9D3A-853B29AAFB3DQ38783203-37E7389D-EC3A-4656-8186-25032E3CF06AQ38960547-E56308B3-F211-4FAF-9CFD-91568326204EQ38982413-8BEE7E15-6000-4F1D-AF17-63D77EFFB2EBQ39164330-676A6DBB-2EC5-4EA9-AEE4-C7AD6CB927AAQ39170244-9F4058C7-E290-4E09-9F4C-09AEC188D446Q39204264-884F460C-E5C2-4C03-AB4B-E52B47D3D3B8Q39290260-6E7526DC-9609-414E-87B3-A958D178B694Q40706988-68017239-9645-4076-B876-8F40B88F2BCA
P2860
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Blood pressure-lowering effect ...... a-analysis of clinical trials.
@en
Blood pressure-lowering effect ...... a-analysis of clinical trials.
@nl
type
label
Blood pressure-lowering effect ...... a-analysis of clinical trials.
@en
Blood pressure-lowering effect ...... a-analysis of clinical trials.
@nl
prefLabel
Blood pressure-lowering effect ...... a-analysis of clinical trials.
@en
Blood pressure-lowering effect ...... a-analysis of clinical trials.
@nl
P2093
P2860
P356
P1476
Blood pressure-lowering effect ...... a-analysis of clinical trials.
@en
P2093
P2860
P304
P356
10.1111/DOM.12085
P577
2013-03-20T00:00:00Z